Media coverage about iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) has trended positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. iShares Nasdaq Biotechnology Index Fund earned a daily sentiment score of 0.29 on Accern’s scale. Accern also assigned headlines about the financial services provider an impact score of 46.5143023276473 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) traded down $0.04 during mid-day trading on Wednesday, hitting $311.27. 897,000 shares of the stock traded hands, compared to its average volume of 1,100,809. iShares Nasdaq Biotechnology Index Fund has a one year low of $261.65 and a one year high of $342.50.

ILLEGAL ACTIVITY WARNING: “iShares Nasdaq Biotechnology Index Fund (IBB) Receives News Sentiment Score of 0.29” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/29/ishares-nasdaq-biotechnology-index-fund-ibb-receives-news-sentiment-score-of-0-29.html.

iShares Nasdaq Biotechnology Index Fund Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Insider Buying and Selling by Quarter for iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with MarketBeat.com's FREE daily email newsletter.